The type 2 deiodinase (D2) has an important role in hypothyroidism, where its ability to activate thyroid hormone provides justification for levothyroxine "monotherapy." A prevalent polymorphism in D2, Thr92AlaD2, has been associated with improved well-being on "combination therapy" with T4+T3; the underlying mechanism is unclear as T4-to-T3 conversion appears normal. Novel studies indicate this might be a risk factor for neurodegenerative disease. If the relationship between Thr92AlaD2-expression and treatment preference is confirmed, personalized medicine may play a role in hypothyroidism.
Extrathyroidal production of the active form of thyroid hormone, T3, via deiodination of thyroxine (T4) provides physiologic justification for the treatment of hypothyroidism with levothyroxine (l-T4) "monotherapy"; 1 T3
production outside of the thyroid gland is mediated largely by the type 2 deiodinase (D2). l-T4-treated patients exhibit stable levels of serum T3 2 and for decades clinicians have attributed this to adequate and consistent peripheral T4-to-T3 conversion. 3,4 Accordingly, the majority of l-T4-treated patients achieve both clinical and biochemical euthyroidism, which is typically defined as normalization of the serum thyroid stimulating hormone (TSH). 5, 6 However, it has been recognized in more recent years that despite normalization of serum TSH, some patients suffer from residual hypothyroid symptoms and, in particular, cognitive complaints. 7 Given the high prevalence of hypothyroidism, which afflicts more than eight million Americans alone, 8 that about 12 % of treated individuals remain symptomatic represents a considerable portion of the population. 7 Therefore, optimization of therapeutic response in hypothyroidism represents an important target for the public health.
Although l-T4-treated patients typically exhibit serum TSH, T4, and T3 levels within the normal range, this occurs at the cost of an elevated serum T4:T3 ratio. 9 With that being said, a minority of patients fail to achieve normal serum T3 levels. 10, 11 One hypothesis to explain residual symptomatology in l-T4-treated patients is localized hypothyroidism within a particular tissue, for example, the brain. D2 is abundantly expressed within this T3-target tissue, and therefore it is logical to consider that a defect in the D2 pathway could result in localized brain hypothyroidism. If this were the case, the ability of "combination" therapy (treatment with T4+T3-containing regimens) to improve psychological parameters in some patients would be explained. 12 In addition to its association with treatment preference in hypothyroidism, Translational studies have helped to define the molecular mechanism underlying the clinical phenotype associated with Thr92AlaD2-expression-stable expression of the Thr92AlaD2 protein in a human cell model modified the cellular environment such that the polymorphic protein had a prolonged half-life and was aberrantly located in the Golgi apparatus, where it perturbed Golgi morphology. 18 When samples of human temporal pole were studied, there was an overlap in the gene expression patterns compared with the cellular model, suggesting for the first time that these cellular alterations might be the cause of a tissue-specific dysfunction within a D2-expressing tissue. Specifically, the transcriptome of the human temporal pole exhibited gene expression pathways that are enriched in neurodegenerative diseases. 18 The concept that Thr92AlaD2-expression confers a genetic profile in the human cerebral cortex congruent with diseases such as Huntington's suggests that further characterization of the clinical phenotype associated with Thr92AlaD2-expression has the potential to transcend the thyroid field.
Other D2-expressing tissues will also need to be studied to assess for tissue-independent patterns of transcriptional abnormalities. If carriers of the Thr92AlaD2 protein exhibit cellular perturbation throughout their D2-expressing tissues, this could explain the association with diverse clinical conditions seen in genome-wide association studies. 
